Clinical trial
Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
NCT00455312 · Masonic Cancer Center, University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00455312 |
|---|---|
| Title | Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA |
| Official title | Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Dyskeratosis Congenita, Aplastic Anemia |
| Intervention type | Drug, Procedure |
| Interventions | Campath 1H, Cyclophosphamide, Fludarabine, Total Body Irradiation, Stem Cell Transplantation, antithymocyte globulin, Methylprednisolone |
| Enrollment | 36 |
| Start date | Aug 1, 2007 |
| Primary completion | Mar 1, 2015 |
| Completion | Jun 1, 2016 |
| First posted | Apr 3, 2007 |
| Last update posted | Dec 5, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: